3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gastrointestinal stromal tumors (GIST) lacking mutations in KIT/PDGFRA or RAS pathways and retaining an intact SDH complex are usually referred to as KIT/PDGFRA/SDH/RAS‐P WT GIST or more simply quadruple WT GIST (~5% of all GIST). Despite efforts made, no recurrent genetic event in quadruple WT GIST has been identified so far. To further investigate this disease, we performed high throughput copy number analysis on quadruple WT GIST specimens identifying a recurrent focal gain in band 11q13.3 (involving FGF3/FGF4) in 6/8 cases. This event was not found in the other molecular GIST subgroups. FGF3/FGF4 duplication was associated with high expression of FGF4, both at mRNA and protein level, a growth factor normally not expressed in adult tissues or in KIT/PDGFRA‐mutated GIST. FGFR1 was found to be the predominant FGF receptor expressed and phosphorylation of AKT was detected, suggesting that a FGF4‐FGFR1 autocrine loop could stimulate downstream signaling in quadruple WT GIST. Together with the recent reports of quadruple WT cases carrying FGFR1 activating alterations, these findings strengthen the hypothesis of a potential involvement of FGFR pathway deregulation in quadruple WT GIST, which may represent a rationale for novel therapeutic approaches.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Biology of gastrointestinal stromal tumors.

          Once a poorly defined pathologic oddity, in recent years, gastrointestinal stromal tumor (GIST) has emerged as a distinct oncogenetic entity that is now center stage in clinical trials of kinase-targeted therapies. This review charts the rapid progress that has established GIST as a model for understanding the role of oncogenic kinase mutations in human tumorigenesis. Approximately 80% to 85% of GISTs harbor activating mutations of the KIT tyrosine kinase. In a series of 322 GISTs (including 140 previously published cases) studied by the authors in detail, mutations in the KIT gene occurred with decreasing frequency in exons 11 (66.1%), 9 (13%), 13 (1.2%), and 17 (0.6%). In the same series, a subset of tumors had mutations in the KIT-related kinase gene PDGF receptor alpha (PDGFRA), which occurred in either exon 18 (5.6%) or 12 (1.5%). The remainder of GISTs (12%) were wild type for both KIT and PDGFRA. Comparative studies of KIT-mutant, PDGFRA-mutant, and wild-type GISTs indicate that there are many similarities between these groups of tumors but also important differences. In particular, the responsiveness of GISTs to treatment with the kinase inhibitor imatinib varies substantially depending on the exonic location of the KIT or PDGFRA mutation. Given these differences, which have implications both for the diagnosis and treatment of GISTs, we propose a molecular-based classification of GIST. Recent studies of familial GIST, pediatric GIST, and variant forms of GIST related to Carney's triad and neurofibromatosis type 1 are discussed in relationship to this molecular classification. In addition, the role of mutation screening in KIT and PDGFRA as a diagnostic and prognostic aid is emphasized in this review.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

            Wild-type (WT) gastrointestinal stromal tumors (GISTs), which lack KIT and PDGFRA gene mutations, are the primary form of GIST in children and occasionally occur in adults. They respond poorly to standard targeted therapy. Better molecular and clinical characterization could improve management.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.

              Gastrointestinal stromal tumors (GISTs), the specific KIT- or PDFGRA-signaling driven mesenchymal tumors, most commonly occur sporadically, but there seems to be some increased tendency for these tumors to develop in patients with neurofibromatosis 1 (NF1). The clinicopathologic profile, KIT, and PDGFRA mutation status and long-term prognosis of patients with GIST in NF1 are incompletely characterized. In this study, we analyzed 45 patients who had NF1 and GIST. There were 26 females and 19 males with a median age of 49 years (10 years lower than the median age of GIST patients in general). A great majority of tumors occurred in the jejunum or ileum, with multiple tumors occurring in 28 cases. Ten patients had a duodenal and one had a gastric GIST. The most common presentations were gastrointestinal bleeding and anemia, and many patients had intermittent bleeding over several years. The majority of the tumors were small and mitotically inactive; only 7 had mitotic activity >5/50 HPFs and 15 tumors were >5 cm. Associated Cajal cell hyperplasia was common. One patient had an intraabdominal peri-intestinal neurofibroma. Five of 35 patients with follow-up died of metastatic disease; all of these had a tumor >5 cm, mitotic rate >5/50 HPFs, or both; three of these tumors were located in the duodenum. The presence of multiple small tumors was not associated with progressive disease. Most patients with long-term follow-up enjoyed a good prognosis; 2 died of other NF1-associated tumors (malignant peripheral nerve sheath tumors, brain tumor). None of the 16 tumors from 15 patients had a KIT exon 9, 11, 13, or 17 or PDGFRA exon 12 or 18 mutation as is typically seen in sporadic GISTs, indicating that GISTs in NF1 patients have a different pathogenesis than sporadic GISTs.
                Bookmark

                Author and article information

                Contributors
                annalisa.astolfi@unibo.it
                Journal
                Genes Chromosomes Cancer
                Genes Chromosomes Cancer
                10.1002/(ISSN)1098-2264
                GCC
                Genes, Chromosomes & Cancer
                John Wiley & Sons, Inc. (Hoboken, USA )
                1045-2257
                1098-2264
                16 April 2019
                September 2019
                : 58
                : 9 ( doiID: 10.1002/gcc.v58.9 )
                : 636-642
                Affiliations
                [ 1 ] "Giorgio Prodi" Cancer Research Center University of Bologna Bologna Italy
                [ 2 ] Department of Pharmacy and Biotechnology FaBit; University of Bologna Bologna Italy
                [ 3 ] Department of Specialized, Experimental and Diagnostic Medicine S.Orsola‐Malpighi Hospital, University of Bologna Bologna Italy
                [ 4 ] Pathology Unit S.Orsola‐Malpighi Hospital, University of Bologna Bologna Italy
                [ 5 ] Laboratory of Oncological and Transplant Molecular Pathology—Pathology Unit S.Orsola‐Malpighi Hospital, University of Bologna Bologna Italy
                [ 6 ] Department of Medical Oncology University Campus Bio‐Medico Rome Italy
                [ 7 ] Medical Oncology Unit 2, Medical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
                [ 8 ] Sarcoma Unit Candiolo Cancer Institute ‐ FPO IRCCS Candiolo Italy
                [ 9 ] Department of Medical and Surgical Sciences S.Orsola‐Malpighi Hospital, University of Bologna Bologna Italy
                [ 10 ] Division of Medical Oncology S.Orsola‐Malpighi Hospital Bologna Italy
                Author notes
                [*] [* ] Correspondence

                Annalisa Astolfi, “Giorgio Prodi” Cancer Research Center, University of Bologna, S.Orsola‐Malpighi Hospital, Via Massarenti 11, Bologna 40138, Italy.

                Email: annalisa.astolfi@ 123456unibo.it

                Author information
                https://orcid.org/0000-0002-2732-0747
                Article
                GCC22753
                10.1002/gcc.22753
                6619263
                30887595
                d35f94e5-f36f-4eec-a7a5-813f2e0c0bd1
                © 2019 The Authors. Genes, Chromosomes & Cancer published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 20 December 2018
                : 07 March 2019
                : 14 March 2019
                Page count
                Figures: 2, Tables: 1, Pages: 7, Words: 5068
                Funding
                Funded by: Petra Srl
                Funded by: Fondazione Isabella Seràgnoli
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                gcc22753
                September 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:10.07.2019

                Oncology & Radiotherapy
                fgf3/fgf4,fgfr inhibitors,fgfr1,gastrointestinal stromal tumours,kit/pdgfra/sdh/ras‐p wt,quadruple wt

                Comments

                Comment on this article